Asensus Surgical (Asensus Surgical) Debt-to-Equity : 0.17 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Debt-to-Equity?

Asensus Surgical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.04 Mil. Asensus Surgical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.65 Mil. Asensus Surgical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $33.41 Mil. Asensus Surgical's debt to equity for the quarter that ended in Dec. 2023 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Asensus Surgical's Debt-to-Equity or its related term are showing as below:

ASXC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 0.17
Current: 0.17

During the past 13 years, the highest Debt-to-Equity Ratio of Asensus Surgical was 0.17. The lowest was 0.02. And the median was 0.08.

ASXC's Debt-to-Equity is ranked better than
55.71% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs ASXC: 0.17

Asensus Surgical Debt-to-Equity Historical Data

The historical data trend for Asensus Surgical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Debt-to-Equity Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.07

0.03

0.06

0.17

Asensus Surgical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.07	0.09	0.12	0.17

Competitive Comparison of Asensus Surgical's Debt-to-Equity

For the Medical Devices subindustry, Asensus Surgical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asensus Surgical's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's Debt-to-Equity falls into.

Asensus Surgical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Asensus Surgical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.036	+	4.646)	/	33.414
	=	0.17

Asensus Surgical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.036	+	4.646)	/	33.414
	=	0.17

Asensus Surgical (AMEX:ASXC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Asensus Surgical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (Asensus Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

2TX:Germany

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Executives

Starling William N Jr	director	2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi	director	C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert	director	343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J.	officer: Chief Technology Officer	635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze	officer: EVP, Chief Financial Officer	C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh	officer: Interim CFO	108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery	officer: EVP and CFO	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith	officer: Chief Commercial Officer	7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope	director, officer: President and CEO	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a	10 percent owner	VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022